Type I interferon is selectively required by dendritic cells for immune rejection of tumorsMark S. Diamond, Robert D. Schreiber|The Journal of Experimental Medicine|2011Cited by 1k
Tumor neoantigens: building a framework for personalized cancer immunotherapyMatthew M. Gubin, Robert D. Schreiber|Journal of Clinical Investigation|2015Cited by 631
STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomasSzeman Ruby Chan, Robert D. Schreiber|Breast Cancer Research|2012Cited by 198
Vav proteins control MyD88-dependent oxidative burstAna V. Miletic, Wojciech Swat, Daniel B. Graham et al.|Blood|2006Cited by 83
Neoantigen landscape supports feasibility of personalized cancer vaccine for follicular lymphomaCody A. Ramirez, Todd A. Fehniger, Alexander Bagaev et al.|Blood Advances|2024Cited by 12